Kai-Uwe Eckardt

Featured in: Favicon

nature.com Favicon

tagesspiegel.de Favicon

thelancet.com Favicon

healio.com Favicon

diabetesresearchclinicalpractice.com Favicon

bmjopen.bmj.com

Articles

Vadadustat for Treatment of Anemia in Patients With Dialysis-Dependent Chronic Kidney Disease Receiving Peritoneal Dialysis

Dec 4, 2024 | digitalcommons.library.tmc.edu | Mark J. Sarnak |Rajiv Agarwal |Neil Boudville |Kai-Uwe Eckardt

BACKGROUND: Hypoxia-inducible factor prolyl hydroxylase inhibitors such as vadadustat may provide an oral alternative to injectable erythropoiesis-stimulating agents for treating anemia in patients receiving peritoneal dialysis.
SGLT2 inhibitors slow CKD progression, may delay dialysis

Oct 12, 2023 | specialty.mims.com | Kai-Uwe Eckardt

Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been dubbed “surprise blockbusters” because of their paradigm-shifting cardiorenal benefits in chronic kidney disease (CKD).

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →